We are thrilled to announce the release of an insightful video lecture titled “Navigating the New Frontiers in Homozygous FH Care” by Professor Peter Lansberg. In this engaging presentation, he delves deep into the complexities of HoFH, offering valuable insights into its diagnosis, management, and treatment options.
Understanding HoFH: Professor Lansberg begins by discussing when to consider HoFH in patients with FH. He sheds light on the key criteria for diagnosing HoFH, providing clinicians with essential guidance on identifying this severe form of hypercholesterolemia.
Managing HoFH Patients: One of the highlights of the lecture is Professor Lansberg’s comprehensive exploration of the management strategies for HoFH patients.
Insights from the Netherlands: Drawing from experiences in the Netherlands, Professor Lansberg presents a compelling case report about an 8-year-old boy, offering real-world perspectives on diagnosing and treating HoFH.
Roadmap FH: In the culmination of the presentation, Professor Lansberg focuses on paper from Global Heart Journal. This paper, which outlines treatment guidelines for FH from the IAS, provides intriguing insights into general strategies, healthcare system setup, and infrastructure required to ensure the accurate diagnosis of FH patients.
ScreenPro FH partners
with FH Europe to build stronger advocacy in Central, Eastern and Southern
Europe.
In the efforts to build a stronger international “one voice” for the Familial Hypercholesterolaemia community, ScreenPro FH is pleased to partner with FH Europe.
With this partnership in place ScreenPro FH intends to collaborate with FH Europe and its members to deliver on our shared mission and reach countries with unmet needs.
Why it is necessary to have a patient organisation? How to establish a patient organization. Practical tips and experiences from Czech Republic and Diagnoza FH patient organisation. You can find the answears and tips in video webinars from Prof. Richard Ceska, ScreenPro FH Project Leader and Kristina Cillikova, Diagnoza FH patient organisation Vice President.
Authors: Tomas Stulc1, Richard Ceska1, Antonio M. Gotto Jr.2
On behalf of the ScreenPro FH Project: Dan GA (Romania), Djuric D (Serbia), Ezhov MV (Russia), Fras Z (Slovenia), Freiberger T (Czech Republic), Gaita D (Romania), Goudev A (Bulgaria), Harangi M (Hungary), Kayikcioglu M (Turkey), Latkovskis G (Latvia), Mark L (Hungary), Mirrakhimov EM (Kyrgyzstan), Mitchenko E (Ukraine), Murataliev TM (Kyrgyzstan), Paragh G (Hungary), Petrulioniene Z (Lithuania), Pojskic B (Bosnia and Herzegovina), Raslova K (Slovakia), Reiner Z (Croatia), Rynkiewicz A (Poland), Susekov AV (Russia), Tasic N (Serbia), Tokgozoglu L (Turkey), Tselepis A (Greece), Vohnout B (Slovakia)
Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. However, most patients who experience adverse symptoms during statin use are able to tolerate at least some degree of statin therapy. Given the profound cardiovascular benefits derived from statins, an adequate practical approach to statin intolerance is, therefore, of great clinical importance. Statin intolerance can be defined as the occurrence of myalgia or other adverse symptoms that are attributed to statin therapy and that lead to its discontinuation. In reality, these symptoms are actually unrelated to statin use in many patients, especially in those with atypical presentations following long periods of treatment. Thus, the first step in approaching patients with adverse symptoms during the course of statin therapy is iden- tification of those patients for whom true statin intolerance is unlikely, since most of these patients would probably be capable of tolerating adequate statin therapy. In patients with statin intolerance, an altered dosing regimen of very low doses of statins should be attempted and, if tolerated, should gradually be increased to achieve the highest tolerable doses. In addition, other lipid-lowering drugs may be needed, either in combination with statins, or alone, if statins are not tolerated at all. Stringent control of other risk factors can aid in reducing cardiovascular risk if attaining lipid treatment goals proves difficult.
You can download complete article HERE.
